Fosun Pharma stock trades at EUR 0.10 with plus 0.00 percent change

Published on 09/30/2026 at 22:35 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Fosun Pharma stock trades at EUR 0.10 with plus 0.00 percent change at Lang & Schwarz on September 30, 2026. H1 adjusted profit rose 19.09 percent to CNY 1.144 billion.

Fosun Pharma, CNE100000536, Illustration mit AI erstellt.

Fosun Pharma stock (ISIN CNE100000536) was trading at EUR 0.10 at Lang & Schwarz on September 30, 2026, at 10:32 p.m. CEST, unchanged versus the prior close of EUR 0.10. The latest corporate event was the resignation of Co-President Wenjie Zhang, effective upon delivery of his letter to the board on September 30, 2026, as Futubull reported.

Leadership change adds a fresh checkpoint

Zhang resigned for personal reasons and will no longer hold positions at the listed company or its controlled subsidiaries, according to Futubull. The announcement gives the market a specific governance data point alongside the company's latest operating figures.

H1 revenue and adjusted profit rise

For the six months ended June 30, 2026, Fosun Pharma generated CNY 20.442 billion in revenue, up 4.75 percent year over year. Adjusted profit attributable to shareholders, excluding non-recurring gains and losses, reached CNY 1.144 billion, an increase of 19.09 percent, while operating cash flow rose 13.59 percent to CNY 2.424 billion, according to the company's PR Newswire release dated September 6, 2026.

The mix also shifted toward innovation and international markets. The same release said the company intends to direct capital toward research and development, share repurchases and interest-bearing debt repayment after the Gland Pharma transaction.

Repurchase plan supports capital allocation

Fosun Pharma announced an H-share repurchase plan of up to HKD 1 billion on September 6, 2026. The plan is designed to be implemented as soon as practicable, with repurchased shares either canceled or held as treasury shares, according to Fosun Pharma.

The company's investor-relations page describes a business spanning pharmaceutical manufacturing, medical devices, diagnostics and healthcare services, with innovation and internationalization as strategic priorities. That operating breadth helps explain why revenue growth, adjusted earnings and cash generation matter together rather than as isolated indicators, according to Fosun Pharma.

Fosun Pharma stock holds at EUR 0.10

At Lang & Schwarz, Fosun Pharma stock was trading at EUR 0.10 on September 30, 2026, at 10:32 p.m. CEST, with a plus 0.00 percent change versus the prior close of EUR 0.10. The Shanghai A-share quote was CNY 24.02 at 3:00 p.m. China Standard Time, with a market capitalization of CNY 63.4 billion and a 52-week range of CNY 20.85 to CNY 30.09 on September 30, 2026.